Trial Profile
A randomised controlled trial to assess the antiplatelet effect of a 600mg (single-dose) and 1,200mg (split-dose) loading dose of clopidogrel and the impact of verapamil, a potent CYP3A4 inhibitor, on the incidence of clopidogrel resistance defined by the VerifyNow (Accumetrics Ltd) P2Y12 platelet function analyzer in patients with coronary disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2016
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Verapamil
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Therapeutic Use
- Acronyms PRINC
- 22 Jun 2016 Results published in the Journal of the American College of Cardiology
- 03 Sep 2011 New trial record